

**DAFTAR PUSTAKA**

- Aktas, Z., Kayacan, C.B., Schneider, I., Can, B., Midilli, K., Bauernfeind, A., 2008. Carbapenem hydrolyzing oxacillinase, OXA-48, persist in *Klebsiella pneumoniae* in Istanbul, Turkey. *Chemotherapy* 54 (2), 101-106.
- Alsterlund, R., Carlsson, B., Gezelius, L., Haeggman, S., Olsson-Liljequist, B., 2009. Multi resistance CTX-M-15 ESBL-producing *Escherichia coli* in southern Sweden: description of an outbreak, *Scand, J. Infect Dis*, 41 (6-7), 410-415.
- Barlow M. 2009. What antimicrobial resistance has taught us about horizontal gene transfer. *Methods in molecular biology* (Clifton, NJ) ; 532:397-411.
- Bhattacharya S. Esbl- from petri dish to the patient. *Indian Journal of Medical Microbiology* 2006; 24: 20-4.
- Brun-Buisson, C., P. Legrand, A. Philippon, F. Montravers, M. Ansquer, and J. Duval. 1987. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant *Klebsiella pneumoniae*. *Lancet* ii:302-306.
- Bradford PA. 2001 Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clinical microbiology reviews* ;14(4):933-51, table of contents.
- Brooks, G.F., Carroll, K.C., Butel, J., Morse, S., 2008. *Mikrobiologi Kedokteran edisi 23*. Jakarta: EGC.
- Bush, K., Jacoby, G. A. 2010. Update Functional Classification of  $\beta$ -Lactamases. *American Society for Microbiology, Antimicrob. Agents Chemother*; Vol. 54, No. 3, Mar 2010, p. 969-967.
- Carattoli, A., 2008. Animal reservoirs for extended spectrum betalactamase producers, *Clin Microbiol Infect.* 1, 144-153.
- Chen L, Mediavilla JR, Endimiani A, Rosenthal ME, Zhao Y, et al. (2011) Multiplex real-time PCR assay for detection and classification of *Klebsiella pneumoniae* carbapenemase gene (*bla* KPC) variants. *J Clin Microbiol* 49: 579–585.
- Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H (2011) High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. *Am J Respir Crit Care Med* 184(12):1409–1417

- Data WLC-i-P. 2014. Antimicrobial resistance: global report on surveillance.; Section 03: The health and economic burden due to antibacterial resistance:36-7.
- Escobar M. Non-Carbapenem Therapy for Bacteremia Caused by Extended-Spectrum  $\beta$ -Lactamase-Producing Enterobacteriaceae When Can We Afford to Bench the Big Three. 2013: 1-16.
- European Center for Disease Control and Prevention (2013) European Antimicrobial Resistance Surveillance (EARS-Net) 2013. [http://www.ecdc.europa.eu/en/healthtopics/antimicrobial\\_resistance](http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance). Accessed 29 Dec 2014
- Falagas ME, Karageorgopoulos DE. Extended-spectrum b-lactamase-producing organisms. *Journal of Hospital Infection* 2009; 73: 345-54.
- Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. 2010. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. *Lancet Infect. Dis.* 10:43–50.
- Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 52:e103–e120. doi:10.1093/cid/ciq257
- Hadi U (2008). Terapi empiris antibiotik pada penderita bakteriemia/sepsis. In: Hadi U, Nasronudin, Bramantono, Triyono EA, Arfianto MV, Soewandojo E, Suharto (eds). *Simposium Nasional Penyakit Tropik-Infeksi dan HIV & AIDS*, 22-23 Maret 2008 Surabaya, p 28-31
- Hauser, A. R. 2013. *Antibiotic Basics for Clinicians: The ABCs of Choosing the Right Antibacterial Agent* 2<sup>nd</sup> Edition. Philadelphia: Lippincott Williams & Wilkins.
- Hawser, S.P., Bouchillon, S.K., Hoban, D.J., Badal, R.E., Hsueh, P.R., Paterson, D.L. 2009. Emergence of high-levels of extended-spectrum- $\beta$ -lactamase-producing gram-negative bacilli in the Asia-Pacific region: Data from the study for monitoring antimicrobial resistance trends (SMART) program 2007. *Antimicrob. Agents Chemother*; 53: 3280–3284.

- Jacoby GBK.  $\beta$ -Lactamase Classification and Amino Acid Sequences for TEM, SHV and OXA Extended-Spectrum and Inhibitor Resistant Enzymes. 2014.
- Jesus RB, Paterson DL. 2006. Change in the Epidemiology of Infections Due to Extended-Spectrum  $\beta$ -Lactamase Producing Organisms. *Clin Infect Dis*. 42(7):935–7.
- Kuntaman, K., Santoso, S., Wahjono, H., Mertaniasih, N.M., Lestari, E.S., Farida, H., Hapsari, R., Firmanti, S.C., AS, N., Santosaningsih, D., Purwono, P.B., Kusumaningrum, D. 2011. The sensitivity pattern of ESBL's (Extended Spectrum Beta Lactamase) Producing bacteria against Six antibiotics that routinely used in Clinical Setting. *Journal of the Indonesian Medical Association* ;61 (12) : 482-6.
- Kjerulf, A., Hansen, D.S., Sandvang, D., Hansen, F., & Frimodt-Moller, N. 2008. The prevalence of ESBL-producing *E.coli* and *Klebsiellae* strains in the Copenhagen area of Denmark. *APMIS*, 116 ; 118.
- Lewis, MT., Yamaguchi, K., Biedenbach, DJ & Jones, RN. 1999. In vitro evaluation of cefepime and others broad-spectrum beta lactams in 22 medical centers in Japan : a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. *Diagn Microbiol Infect Dis*, 35 ; 307.
- Maraki S, et al. 2009. Susceptibility of urinary tract bacteria to fosfomycin. *Antimicrob. Agents Chemother*. 53:4508–4510.
- Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. *Antimicrobial agents and chemotherapy*. 2000;44(7):1771-7.
- Mayers, D.L., Lerner, S.A., Ouellette, M., Sobel, J. D. 2009. *Antimicrobial Drug Resistance Volume 1 : Mechanisms of Drug Resistance*. New York : Humana Press.
- Mayers, D.L., Lerner, S.A., Ouellette, M., Sobel, J. D. 2009. *Antimicrobial Drug Resistance Volume 2 : Clinical and Epidemiological Aspects*. New York : Humana Press.
- National Health Services, 2014. UK Standards for Microbiology Investigations: Identification of Enterobacteriaceae. Public Health England. Available [http://www.hpa.org.uk/webc/hpawebfile/hpaweb\\_c/1313155004720](http://www.hpa.org.uk/webc/hpawebfile/hpaweb_c/1313155004720) [Accessed on 21 April 2014]

- Oteo J, et al. 2010. Parallel increase in community use of fosfomicin and resistance to fosfomicin in extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli*. *J. Antimicrob. Chemother.* 65:2459–2463.
- Otman, J., Cavasin, ED., Perugini, ME & Vidotto, MC. 2002. An outbreak of extended-spectrum beta lactamase-producing *Klebsiella* species in a neonatal intensive care unit in Brazil. *Infect Control Hosp Epidemiol*,23; 8
- Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. *Clinical microbiology reviews*.18(4):657-86.
- Pilmis B, Jullien V, Tabah A, et al.: Piperacillin-tazobactam as alternative to carbapenems for ICU patients. *Ann Intensive Care.* 2017; 7(1): 113.
- REA-Raisin Network. 2012 Surveillance of nosocomial infections in critically ill adult patients, France, 2012. <http://www.cclinparisnord.org>. Accessed 26 Dec 2014
- Rice, L.B., Willey, S.H., Papanicolaou, G.A., Medeiros, A.A., Eliopolous, G.M., R,C,J., Jacoby, G.A., 1990. Outbreak of ceftazidime resistance caused by extended-spectrum beta lactamases at Massachusetts chronic-care facility. *Antimicrob, Agents Chemother*, 34 (11), 2193-2199.
- Rice, L. B., L. L. Carias, A. M. Hujer, M. Bonafede, R. Hutton, C. Huyen, and R. A. Bonomo. 2000. High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 44:362-36
- Rodriguez-Bano, J., Paterson, DL. 2006. A change in the epidemiology of infections due to extended-spectrum Beta lactamase-producing organism. *Clin Infect Dis*, 42(7);935-937.
- Rodriguez-Rojas A, et al. 2010. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomicin treatments for *P. aeruginosa* infections. *PLoS One* 5:e10193. doi:10.1371/journal.pone.0010193.
- Rodríguez-Bañ o J, Navarro MD, Retamar P, Pico´n E, Pascual A, and the Extended-Spectrum Beta-Lactamases–Red Española de Investigació n en Patología Infecciosa/Grupo de Estudio de Infecció n Hospitalaria Groups. b-Lactam/b-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum b-Lactamase–Producing *Escherichia coli* A Post Hoc Analysis of Prospective Cohorts. *CID* 2012; 54: 167-74.

- Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA et al (2012) International Nosocomial Infection Control Consortium Additional file Additional file 1: Table S1. Intrinsic beta-lactam resistance in clinically relevant Enterobacteriaceae species. Table S2. Aminoglycoside-modifying enzymes in Gram-negative bacilli: main clinically relevant types and corresponding resistance profiles. (INICC) report, data summary of 36 countries, for 2004–2009. *Am J Infect Control* 40(5):396–407
- Rupp ME, Fey PD. Extended Spectrum  $\beta$ -Lactamase (ESBL)-Producing Enterobacteriaceae Considerations for Diagnosis, Prevention and Drug Treatment. *Drugs* 2003; 63: 353-65.
- Ruppé É, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. *Ann Intensive Care*. 2015;5:61.
- Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014 Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). *Diagn Microbiol Infect Dis* 78(4):443–448
- Senol S, et al. 2010. Carbapenem versus fosfomicin tromethanol in the treatment of extended-spectrum beta-lactamase-producing *Escherichia coli*-related complicated lower urinary tract infection. *J. Chemother.* 22:355–357.
- Sheu CC, Lin SY, Chang YT, et al.: Management of infections caused by extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae: current evidence and future prospects. *Expert Rev Anti Infect Ther.* 2018; 16(3): 205–18.
- Smith, P. W., C. W. Seip, S. C. Schaefer, and C. Bell-Dixon. 2000. Microbiologic survey of long-term care facilities. *Am. J. Infect. Control.* 28:8-13.
- Swhwaber, M.J., Carmeli, Y. 2007. Mortality and delay in effective therapy associated with extended spectrum  $\beta$ -lactamase production in Enterobacteriaceae bacteremia; a systemic and metaanalysis. *J Antimicrob Chemother*; 60(5):913-920.
- Tham, J., 2012. Extended Spectrum Beta Lactamase Producing Enterobacteriaceae: Epidemiology, Risk Factors and Duration of Carriage. Lund University. Available from: <http://lup.lub.lu.se/record/3045564/file/3045665.pdf> [Accessed on 2 April 2014]

Vaidya VK. Horizontal Transfer of Antimicrobial Resistance by Extended-Spectrum beta Lactamase-Producing Enterobacteriaceae. *Journal of laboratory physicians*. 2011;3(1):37-42.